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In this review, we aim to lead the readers through the historical highlights of
pathophysiological concepts and treatment of asthma. Understanding the nature and
links of asthma has modeled our diagnostic, pathophysiological and therapeutic thinking
and acting. The recognition of its heterogeneous nature in combination with several
reﬁned and sophisticated technologies will mark a new era of phenotype-speciﬁc approach
and treatment of asthma.
& 2006 Elsevier Ltd. All rights reserved.Introduction
With the centennial anniversary of Respiratory Medicine,
this article summarizes some of the history of asthma. The
journal started in 1907 as British Journal of Tuberculosis
(1907–42), changed into the British Journal of Tuberculosis
and Diseases of the Chest (1943–58) and subsequently into
the British Journal of Diseases of the Chest (1959–88). As a
result of the changing clinical and scientiﬁc interests based
on disease prevalence and developing technologies, there
has been a shift in the focus of topics. In the ﬁrst 50 years of
the journal, the number of published articles on asthma was
around 20, mounting to over 700 in the past decade alone.
Apart from the increasing prevalence over the years, the
deﬁnition, insights into and the understanding of pathophy-
siology and the associated treatment modalities of asthma
changed due to methodological advances and controlled-
randomized trials.Elsevier Ltd. All rights reserved.
(Z. Diamant).Concepts on the aetiology of asthma
throughout the centuries
In ancient times, asthma was already recognized in many
cultures, including the Chineses’, Hebrews’, Greeks’ and
Romans’. The Greek physician Hippocrates (460–377 BC) ﬁrst
described asthma, which is derived from the Greek word
‘‘asthmaino’’ (astZmaino) indicating ‘‘panting or gasping’’.
The ﬁrst aetiological link with bronchospasm was made by
Galen (130–201 AD), who also described the association
between upper and lower airways.1,2
From ancient times throughout the middle ages, there
was little interest in asthma and the term was mainly
applied for cardiac and pulmonary dyspnoeic disorders.
At that time physicians considered the paradigms by
Hippocrates and Galen as golden standard. Evidently,
treating kings and nobility, inspired physicians to search
for novel aetiological links and therapeutic options for
asthma: largely derived from trial and error in single
patients or based on personal conviction. In his Treatise on
asthma, Maimonides (1135–1204), physician of sultan
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opium, good personal and environmental hygiene and
emphasized the importance of dietary factors.1,2
In the 16th century, the German physician Georgius
Agricola (formerly Georg Bauer; 1494–1555) described the
association between environmental factors and airway
symptoms and was possibly the ﬁrst to report occupational
asthma. He suggested to prevent asthma in miners with
protective masks to avoid the inhalation of dust.3 In the
Renaissance period airway symptoms associated with ex-
posure to seasonal allergens were already reported.2,3 At
that time, avoidance of some allergenic factors and cold
baths (once in 14 days or once a month) were the mainstay
of asthma therapy.3
Bronchial asthma in its modern deﬁnition dates back to
the early 19th century, when it was recognized as a unique
airways disorder characterized by bronchospasm following
Rene Laennec’s (1781–1826) invention of the stethoscope.2,3
In addition, the familial clustering of asthma and allergy was
appreciated.
In 1860, Henry Hyde Salter (1823–71) proposed a
classiﬁcation into extrinsic and intrinsic asthma, based on
the nature and putative mechanism of various stimuli (e.g.
animal dander or emotional stress) inducing episodes of
bronchospasm.4 Some 30 years later, William Osler
(1849–1919) described the link between various (non)spe-
ciﬁc stimuli causing paroxysmal airways dysfunction in
asthma—later recognized as bronchial hyperresponsiveness.
Osler considered asthma as an inﬂammatory disease, based
on several pathological changes within the asthmatic
airways including oedema, gelatinous mucus, and Charco-
t–Leyden crystals (‘asthma crystals’) in the sputum.5 The
identiﬁcation of the asthma crystals as eosinophil granulo-
cytes came when Paul Ehrlich (1854–1915) discovered
tetrabromoﬂuorescein (eosin).6 Using aniline stainings Ehr-
lich also identiﬁed mast cells and basophils.
In the beginning of the 20th century, the hereditary and
heterogeneous nature of asthma, its relationship with
several allergies and its neural, inﬂammatory, and vascular
mechanisms gained interest.7 An early letter in this journal
reports on the controversies in these days: while a French
group regarded asthma as ‘‘urace´mie respiratoire’’ occur-
ring on an ‘‘arthritic diathesis’’, contemporary physicians
rather referred to a ‘‘colloidoclassic diathesis’’. And as the
author states: ‘‘these views were largely based upon clinical
experience’’; and hence, it was felt that more experimental
work was needed to fund these hypothesis.8 Furthermore,
during a long period of time, the neuro-psychogenic origin of
asthma has been entertained.9 This concept has gained
renewed interest in recent years.10,11 Others felt that ‘‘the
sensitive nerves of the diaphragm are stretched and
irritated, resulting in shortness of breath and a feeling of
oppression which occurs especially during the night’’.12
Although neuro-psychological aspects were still considered
of pivotal importance, following the discovery of allergic
mechanisms, the origin of asthma was largely regarded as
allergic.
While at that time inhaled allergen provocation was the
mainstay for diagnosis of allergic asthma, this changed with
the discovery of IgE and the possibility to measure speciﬁc
IgE antibodies. However, Francis Rackemann (1887–1973)
described patients with asthma without any evidence ofallergic triggering of their symptoms and hence coined the
term ‘intrinsic asthma’.13 Similarly, attempting to classify
asthma on the basis of provoking agents in 1971, Margaret
Turner-Warwick concluded that ‘there remains a group of
patients in whom asthmatic symptoms are unrelated to any
demonstrable agent and where prick skin tests remain
negative even when challenged with a wide range of
antigens’.14
Although previously reported by Osler, bronchial or airway
hyperresponsiveness as a major pathophysiological charac-
teristic of asthma was ﬁrst quantiﬁed in 1946 by Curry, who
examined the effects of increasing doses of inhaled
histamine in subjects with and without asthma.15 Even-
tually, these experiments resulted in one of the most
reliable diagnostic tools for asthma.
The concept, that asthma is an inﬂammatory disorder was
ﬁrmly established in the 20th century, which also marked
the advent of interventional randomized control trials, the
development of invasive and non-invasive methodologies
and emerging immunological technologies, which increas-
ingly replaced personal experience and observations. Airway
remodelling, another important feature of asthma, has ﬁrst
been reported in this journal by Ellul-Micallef in 1973.16
Applying ﬂexible bronchoscopy, Laitinen and colleagues
were amongst the ﬁrst to report the structural changes
within the airways of asthmatics.17 From that time on, an
expanding number of (interventional) studies applying
submucosal and even transbronchial biopsies have been
conducted that helped to deﬁne the immuno-histopatholo-
gical changes within the asthmatic airways. Presently, there
are 2 major hypothesis on airway remodelling: while the
structural airway changes are mostly regarded as a
consequence of chronic airway inﬂammation,18 some view
airway remodelling and chronic airway inﬂammation as
parallel processes, since airway wall changes can be present
even in the absence of a long-standing history of asthma
(Fig. 1). Presently, it is debated whether airway remodelling
may account for the accelerated decline in lung function in
severe persistent asthma or whether structural changes
within the airways may serve a protective purpose.18,19
During the last decade of the 20th century, another long-
standing concept, namely the systemic features of the
allergic–asthmatic inﬂammation including the concept of
uniﬁed airways, which was introduced by Galen almost 2000
years ago, were reinvented.20Evolution of the current concepts on the
pathophysiology and immunology of asthma
For many years asthma was considered to have a psychoso-
matic background; as a consequence psychopharmaca were
used to ‘‘lessen emotional tension in asthma’’ in the 20th
century.21 Furthermore, the importance of airway smooth
muscle in the pathophysiology of asthma has been en-
tertained for centuries.16 Therefore, early anti-asthma
strategies mainly aimed at relieving bronchospasm with
bronchodilator agents, such as coffee and tea. In the 20th
century, their mechanism of action was conﬁrmed by
observations that asthmatic bronchi dilate in response to
theophylline (derivates) and b2-agonists.22,23 During the
past decade, there has been renewed interest in the airway
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Figure 1 Pathophysiological mechanisms of airway remodelling in asthma.
Z. Diamant et al.380smooth muscle cells for their role in the pathophysiology of
airway hyperresponsiveness and remodelling, and for their
interaction with other (inﬂammatory) effector cells of
asthma.24–26
In 1966, another milestone of pathophysiological evi-
dence came with the discovery of (speciﬁc) IgE and its role
in mast cell activation.27 Histamine, one of the key pro-
inﬂammatory mediators released from mast cells, had
already been implicated in the pathophysiology of asthma
since 1911, when Dale and Laidlaw induced anaphylaxis with
histamine in laboratory animals.28 Human experiments
suggested a pivotal role for histamine in the asthmatic
response and, hence, researchers determined histamine
levels in blood.28 Indeed, some authors claimed therapeutic
effectivity of antihistamines in the treatment of (childhood)
asthma.29 After the initial hype, the interest in mast cells
decreased again, mainly due to the limited potency of
antihistamines in most asthmatics.30 However, there is now
renewed interest in the role of mast cells in airway
hyperresponsiveness in asthma, as there is evidence that
they might interact with airway smooth muscle cells within
the airway wall.24–26
In the 1990s, ﬂexible bronchoscopy helped to establish
the concept of a skewed T-helper (TH) cell proﬁle in asthma
with a predominance of TH-2 cells and a related cytokine
proﬁle which is associated with both airway eosinophilia and
IgE-production.31 These ﬁndings led to a plethora of
investigations into the role of T-cells and their products in
the pathogenesis of asthma among which IL-5 and its
regulatory role on eosinophils appeared to explain many
features of the asthmatic inﬂammation.31,32 However, IL-5
antibodies failed to abolish the features of asthma despite
removing eosinophils,33,34 which redeﬁned the role of
eosinophils in the pathophysiology of asthma: both the
involvement in airway inﬂammation and in the process of
airway remodelling.35,36 Although eosinophilic inﬂammation
was considered crucial in the pathophysiology of asthma,
severe persistent asthma has increasingly been recognized
as an immunologically different subset with a predominantly
neutrophilic airway inﬂammation.37In recent years, the role of growth factors, neurotrophins
and genetic factors has become a focus of interest in the
pathophysiological context of asthma.11,38,39 Yet, none of
these hypotheses has been able to fully explain the
pathophysiology of asthma. Similarly, interventions target-
ing any of the mentioned substrates have only partially
reversed the pathophysiological features with little impact
on the overall asthma severity.Triggering factors and clinical phenotypes and
presentations of asthma
Clinically, there are several phenotypes of asthma. World-
wide, the atopic phenotype (‘‘extrinsic asthma’’) seems to
have a higher prevalence than the non-atopic phenotype
(‘‘intrinsic asthma’’).40 Allergic asthma generally starts in
childhood or adolescence, and thus has a high prevalence in
mainly younger individuals suffering from airway symptoms in
response to common aeroallergens but sometimes also in
response to occupational agents. Most patients with allergic
asthma have a positive family history of atopy or other
allergic diseases. Alternatively, some patients develop
asthma at a later age (‘‘adult onset asthma’’), often as a
consequence of viral respiratory infections. Unlike in the
allergic phenotype, in these patients total and speciﬁc serum
IgE-concentrations are commonly not elevated and symptoms
are not precipitated by environmental allergens (‘‘intrinsic
asthma’’). Although sometimes referred to as ‘infectious
asthma’ this has to be considered a misnomer since
exacerbations in response to respiratory tract infections are
common to both allergic and intrinsic asthma. Although some
investigators tried to ﬁnd allergies against infectious agents
in intrinsic asthma, this has never been conclusively
substantiated. There are a few studies reporting on clear
immunological differences between allergic and intrinsic
asthma. Apart from airway eosinophilia found in both subsets,
Walker and colleagues reported distinct patterns of T-cell
activation yielding different cytokines in peripheral blood and
bronchoalveolar lavage of subjects with allergic and non-
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progress to Churg Strauss Syndrome has been debated but
early observations suggest a common clinical pathway
between intrinsic asthma and asthma with polyarteritis
nodosa, where ‘‘there is no family history of allergic disease;
the onset is often later in life than in the case of allergic
asthma; loss of weight may be considerable; high eosinophilia
is general, and often exceeds 5000/mm; chest X-rays
frequently show transient inﬁltrations and asthma can be
successfully treated with oral corticosteroids’’.42
When the British Thoracic Society investigated asthma
death in relation to their atopic status, they found that atopic
asthmatics were more likely to die of acute asthma, most
often in the months of May/June and September/October and
mostly on weekends, whereas non-atopic asthmatics had a
higher risk of suffering a fatal asthma attack in the months of
January to April without a predilection during the week.43
These ﬁndings again underscore the difference in trigger
factors and mechanisms involving asthma attacks between
allergic and non-allergic asthma. Although less common than
allergic asthma, Ulrik and colleagues report non-atopic
intrinsic asthma in children.44 As was observed after 1 year
in their study, this asthma subset appeared to have different
predictors and outcome parameters and was, therefore,
considered to have a different pathogenesis.44
In addition, there is a group of patients whose asthma
initially starts with allergen-dependent symptoms but
progresses to a less allergen-dependent subtype. Although
skin test reactivity remains present in these individuals,
their clinical response to allergen wanes. Consequently,
these patients clinically often behave very similar to those
with intrinsic asthma and hence are referred to as ‘mixed
type asthma’. Some 50 years ago, these patients have been
clinically described as ‘‘having a characteristic story of
intermittent asthma from childhood’’y whichy ‘‘at some
point became complicated by persistent cough with spu-
tum’’. Thus, continuous wheezing with breathlessness
replaced the earlier intermittent asthmatic attacks and
‘‘recurrent winter colds on the chest’’ became a further
regular complication.45
Occupational asthma has been often classiﬁed as a
distinct asthma-subset, based on its various presentations
with or without IgE-mediated symptoms. For example,
bakers’ asthma (induced by ﬂour) is IgE-mediated and
strongly resembles allergic asthma. Alternatively, low
molecular weight sensitizers, such as isocyanates, may
cause asthma without measurable IgE-antibodies with a
number of features similar to non-allergic or intrinsic
asthma. Meadway found no clear relationship between
atopic status or skin rashes to resin and a fall in FEV1 in
patients who presented with asthmatic symptoms following
exposure to epoxy resins.46
Exercise-induced asthma has also gained much interest.
Exercise-induced bronchoconstriction occurs in allergic as
well as non-allergic asthma and is most likely due to thermal
and osmotic changes in the hyperresponsive airways follow-
ing hyperventilation during exercise. In this journal,
Anderson and colleagues have written a comprehensive
historical review on this topic.47
Viruses are important triggers of asthma attacks but
possibly also causative agents in the pathogenesis of asthma
in certain patients.48In addition to phenotypes, asthma can be classiﬁed
according to its severity, ranging from intermittent to (mild,
moderate and severe) persistent.49 Interestingly, mild to
moderate persistent asthma is often associated with atopy,
whereas the severe persistent or ‘‘refractory/difﬁcult-to-
treat’’ phenotype is a more heterogeneous disorder, that
can be subdivided into different clinical or pathophysiolo-
gical subsets with various comorbidities, requiring a
customized therapeutic approach.50,51
Clinically, asthma and chronic bronchitis are sometimes
difﬁcult to separate. Nevertheless, is has been suggested
that the ‘‘use of such a term as ‘‘asthmatic bronchitis’’
should be avoided’’ as it was deemed ‘‘inaccurate and likely
to prove misleading’’.52 In 1986, Wardman et al. reported
that in a general practice, a clear differentiation between
asthma and COPD was difﬁcult in 1/3rd of the patients.53
Currently, it is unclear whether this has improved.
Therapeutic options: past and present
Early anti-asthma regimens largely aimed at relief of
symptoms or modiﬁcation of external factors, applying plant
extracts, life-style adaptations, surgery, or hypnosis for the
relief of asthma.12,54 Apart from these treatment options, in
the pre-inhaler era, early pharmacotherapy consisted of
inhaling the smoke of the so-called ‘‘asthma cigarettes’’,
containing various relieving compounds including atropine,
belladonna, menthol, morphine or cocaine.55 Furthermore,
since asthma was considered to have a psychological origin,
psychopharmaca such as chlorpromazine were prescribed.21
However, none of these ‘‘control’’-aiming therapies proved
effective, while some treatment options such as early
immunotherapeutic vaccines and the use of opiates appeared
hazardous.55 While at that time asthma therapy was pre-
dominantly based on trial and error, targeting inﬂammatory
mechanisms came in the course of mainly the second half of
the 20th century with the discovery of pathological, patho-
physiological and immunological substrates following the
invention and/or reﬁnement of spirometry, ﬂexible broncho-
scopy and immunological techniques.
Xanthines
For centuries, strong coffee and tea were recommended for
the relief of dyspnoea due to bronchospasm. While at that
time practitioners were most likely not aware of the
pharmacological mechanism, i.e. bronchodilator effects
through inhibition of phosphodiesterase (PDE); this was
probably the ﬁrst application of xanthines in the treatment
of asthma. The anti-asthmatic effect of theophylline was ﬁrst
described by Hirsch in 1922.56 Subsequently, theophylline
followed by its more soluble derivate aminophylline in 1937,
became the most widely prescribed drugs for asthma for about
four decades.57,58 However, in clinical practice, theophylline
showed limited efﬁcacy with serious side-effects at higher
doses due to its narrow therapeutic window.58,59 These
disadvantages and the advent of the superior sympathicomi-
metics ﬁnally led to its relegation to second/third line anti-
asthma treatment in developed countries during the
1980s.49,60–62 In recent years, interest revived in xanthine-
derivates due to their oral formulation and low cost. Moreover,
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properties,63,64 through the suppression of the inﬂammatory
gene transcription by activation of histone deacetylase
(HDAC), which is the key target for corticosteroids.65 This
mechanism may explain the beneﬁcial effects on asthma
control reported by several investigators when combining (low
dose) theophylline with inhaled corticosteroids (ICS).66,67
Recently, additional anti-inﬂammatory effects have been
reported, including the acceleration in eosinophil apoptosis
and the decrease in recruitment of lymphocytes and neutro-
phils into the airways.64,68 These properties may be promising
in the treatment of severe asthma or COPD.64 Although initially
classiﬁed as a PDE inhibitor, the pharmacological effects of
theophylline appear much broader and largely not yet
identiﬁed.
In parallel with the renewed interest in theophylline,
there has been development of several more speciﬁc PDE-
inhibitors in the last decade. Despite a better tolerability of
these drugs, the gastrointestinal side effects are still
substantial.69 Targeting PDE-3 has been shown to produce
bronchodilation.70 Alternatively, targeting the major iso-
form within airway inﬂammatory cells, speciﬁc PDE-4
inhibitors (e.g. roﬂumilast and cilomilast) have been
developed for the treatment of asthma and COPD, although
with varying success.71–73 Future studies in asthma applying
combined PDE-3/4 inhibitors should demonstrate their
putative superior effectivity.70b2 agonists
Although the use of adrenal substances in asthma dates back
to 1900,74 in the 1940s epinephrine (or adrenaline) becameMDI orSublingual or 
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Figure 2 Structure and mechanism of action of the mostthe standard bronchodilator therapy for the treatment of
acute asthma.75 However, due to its non-speciﬁc mechanism
of action, the use of epinephrine was complicated by
several—mostly cardiovascular—side effects.76 A break-
through came in the beginning of 1960s with the discovery
of the adrenergic receptor subsets, yielding the a and b
receptor, with a further subdivision into the b1 receptor,
mainly located in the heart and intestinal smooth muscle,
and into the b2 subset on bronchial and uterus smooth
muscle.77,78 Isoprenaline was the ﬁrst agonist interacting
with b adrenergic receptors, while salbutamol, and later on
terbutaline, were the ﬁrst agonists with a higher speciﬁcity
for b2 adrenergic receptors.79,80 Soon after its development
in 1968, salbutamol rapidly became—and still is—the most
widely used fast-acting reliever for asthma.49 The success of
salbutamol initiated the development of several other short-
acting b2 agonists (SABAs), like carbuterol, clenbuterol and
fenoterol, with a duration of action up to 6 h.81,82 The ﬁnal
step for this class of drugs came in 1980s with the
development of long-acting b2 agonists (LABAs). Salmeterol
was ﬁrst launched with a duration of action up to 12 h,83
followed by formoterol. The latter drug combines long-
lasting bronchodilatator effects (412 h) with a fast onset of
action, similar to salbutamol (Fig. 2).84 Currently, several
novel LABAs are being developed with a duration of action
up to 24 h, creating the possibility of once daily dosing.85
The mechanism of action of b2 agonists is predominantly
bronchodilator through airway smooth muscle relaxation,
despite modest anti-inﬂammatory activity encountered in
some studies.86,87 Formerly prescribed as ‘‘4–6 times daily’’
maintenance therapy, current guidelines now recommend
SABAs on ‘‘as needed’’ basis.49 This change of view came
with the growing understanding that airway inﬂammation isMDI or DPIMDI or DPInebulized
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inﬂammation should be the primary goal of asthma treat-
ment, as different from ‘‘symptoms control’’ only. Moreover,
several studies in asthma provided evidence that main-
tenance therapy with both SABAs and LABAs— in or without
combination with ICS— is associated with potential masking
of the airway inﬂammation.88,89 In addition, despite
concomitant use of ICS, maintenance therapy with LABAs
has been shown to induce tolerance to its bronchoprotective
effects and cross-tolerance to the bronchodilator effects of
SABAs.90–93 Finally, data from several studies show that
patients who are homozygous for arginine (Arg/Arg) as
opposed to glycine (Gly/Gly) at the 16th amino acid position
of the b2 adrenergic receptor have an impaired therapeutic
response to b2 agonists.94,95 In these patients, long-term
treatment with albuterol has been found to be associated
with signiﬁcant decrease in lung function over time.94 Some
of these deleterious effects during long-term use of LABAs
with or without an adequate dose of ICS may have resulted
in an increased morbidity and even asthma deaths in the
recently reported SMART study.96 Present guidelines, there-
fore, favour maintenance therapy with LABAs only in
combination with appropriate doses of corticosteroids in
the more severe disease (treatment steps 3–5).49,97
Anticholinergics
During several centuries, the most controversial modality of
asthma treatment has probably been the ‘‘asthma cigar-
ette’’. The active ingredient of these cigarettes consisted of
alkaloids from the Belladonna plant, delivered to the lung by
smoking. This therapy has been advocated for the treatment
of asthma until the middle of the 20th century. At that time
empirically based, today we know that the mechanism of
action was largely caused by the ingredients’ anticholinergic
properties. In the late 1970s, this knowledge resulted in the
development of ipratropium, a synthetic anticholinergic, for
the treatment of asthma. Ipratropium, and the later
developed, long-acting tiotropium, both antagonize the
effect of acetylcholine at the muscarinic M1 and M3
receptor. Despite still a limited role in the treatment of
asthma, anticholinergics may beneﬁt patients with geneti-
cally determined adverse responses to b2 agonists—up to
20% of the asthma population.95 In addition, during an acute
exacerbation when response to SABAs is poor, addition of an
anticholinergic may provide a faster-onset relief.98,99
Cromones, antihistamines and ketotifen
Since mast cells have been thought to play a key role in the
pathophysiology of asthma, in the 1970s these cells and
their pro-inﬂammatory products became major focus of
anti-asthma pharmacotherapy.100,101 Traditionally, cro-
mones (Cromolyn and Nedocromil) have been termed ‘‘mast
cell stabilizers’’. Their mechanism of action has been based
on inhibiting the release of pro-inﬂammatory mediators
from mast cells following IgE-cross linking. However, sodium
cromoglycate caused only a modest inhibition (of 10–20%) of
the mast cell mediator release accompanied by a rapid-
onset tachyphylaxis in in vitro studies.102,103 In clinical
studies of asthma, the overall efﬁcacy of cromones was onlymarginally better than placebo, although clearly inferior to
ICS.104–108 Presently, treatment with cromones is conﬁned to
very mild disease, as add-on therapy in severe chronic
asthma or in special patient populations.104,109,110
Although an important pro-inﬂammatory mediator of
asthma, allergy and anaphylactic shock, pharmacotherapy-
targeting histamine, the major release product of mast-
cells, has been shown to be of little if any effect on asthma
control.63,111,112 Ketotifen, a drug inhibiting the release of
pro-inﬂammatory mediators (histamine and leukotrienes)
from mast cells and basophils combined with H1-antagonis-
tic activity, showed inferior anti-inﬂammatory effect in
asthma when compared with cromoglycate and
ICS.108,113,114 Therefore, current evidence does not support
a predominant role for this category of drugs in the mainstay
treatment of asthma.49Corticosteroids
The ﬁrst reports of corticosteroids in the treatment of
asthma date back some 50 years ago. At that time, these
drugs were administered either intravenously or orally with
good therapeutic results.115,116 However, the initial enthu-
siasm was dampened by the serious side effects accompany-
ing long-term use of systemic corticosteroids, conﬁning their
systemic application to severe cases and exacerbations
only.49 In the early 1970s, the ﬁrst topically active,
aerosolized corticosteroid, beclomethasone diproprionate
(BDP), was introduced into clinical practice.117,118 This ICS
showed effectivity in the treatment of asthma without the
adverse effects associated with prednisone.119,120
Interestingly, the widespread use of ICS started some 20
years later, most likely as a result of the increasing evidence
that asthma is an inﬂammatory disease and the effect of this
paradigm-switch on the concurrent guidelines for asthma
treatment.49,121,122
Corticosteroids are currently the most effective anti-
inﬂammatory drugs for the treatment of persistent asthma.
Especially, prolonged treatment with ICS has been shown to
result in sustained improvement of symptoms and lung
function in combination with a decrease in rescue medica-
tions, exacerbations and airway hyperresponsiveness in
adults and children.123,124 These effects are mediated
through the intracellular glucocorticoid receptor in a large
variety of (inﬂammatory) cells, resulting in both suppression
of inﬂammatory gene transcription and activation of anti-
inﬂammatory gene transcription.125,126
In the past two decades, modiﬁcation of the initial
compounds and inhalers increased the potency and ﬁrst-pass
metabolism in combination with an improved lung deposi-
tion. Presently, available ICS differ little in clinical efﬁcacy
and side effects, ﬂuticasone and budesonide being the most
widely used alone or in combination with a LABA in one
inhaler device (Fig. 3). Being a pro-drug, the recently
launched ciclesonide combines the advantages of a pro-
longed activity (once daily use) with still less (local and
systemic) side effects127–129 (Fig. 3).
However, despite their established clinical effectivity,
even prolonged treatment with high doses of ICS can neither
fully reverse all chronic aspects of the airway inﬂammation
nor cure the disease.130,131
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Figure 3 Structure and major advantages and disadvantages of the most widely used corticosteroids.
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In parallel with the discovery of other components of the
airway inﬂammation in asthma, in 1940 Kellaway and
Trethewie discovered the ‘‘slow reacting substance of
anaphylaxis’’, which appeared to constitute of leuko-
trienes.132,133 In the last two decades of the 20th century,
a large array of studies on leukotrienes have been conducted
both in healthy volunteers and in patients with asthma.
Apart from their bronchoactive properties, leukotrienes
appeared to mimick several other features of asthma,
including airway hyperresponsiveness, airway inﬂammation
and airway remodelling.134 The discovery of leukotrienes
introduced a new focus in asthma research and the
subsequent development of anti-mediator drugs. Unlike
other anti-mediator drugs (including antihistamines, plate-
let activating factor- and prostaglandin inhibitors), potent
anti-leukotrienes effectively reduced several features of
asthma in both adults and children.135,136 In the second half
of the 1990s, the leukotriene synthesis inhibitor, zileuton,
and the leukotriene receptor antagonists (LTRAs), pranlu-
kast, zaﬁrlukast and montelukast entered into clinical
practice: a novel class of anti-asthma therapy since 25
years.136 Although not quite as potent as corticosteroids,
LTRAs combine anti-inﬂammatory—mainly anti-eosinophili-
c—activity with mild, bronchodilator properties, based on
antagonism of cysteinyl leukotrienes (CysLTs) at the CysLT1-
receptor within the airways and on inﬂammatory
cells.134–137 Presently, application of LTRA has been ap-
proved for both adults and children in most steps of the
asthma management plan, mainly as add-on medication,with a recent extension to virally induced bronchoconstric-
tion and asthma with allergic rhinitis.49,138–141 Another—-
more speciﬁc—application for LTRA is aspirin-induced
asthma, recently referred to as Aspirin-Exacerbated Airway
Disease—AERD.137 Interestingly, in this journal Szczeklik and
Nizankowska reported not only patients with an increased
sensitivity to aspirin (aspirin-induced asthma), but also a
small number of patients with asthma who had a broncho-
dilator response to aspirin.142Speciﬁc, novel and future therapies
In the past two decades, controlled randomized trials in
conjunction with modern technologies have greatly ex-
panded our knowledge of the immunology of asthma and its
systemic links. Although interfering with the inﬂammatory
cascade dates back to the early experiments with immu-
notherapy,55 increased understanding of the immunological
basis initiated the development of several targeted thera-
pies for asthma and related syndromes.
Recently, subcutaneous Omalizumab (a humanized mono-
clonal antibody, RhuMab-E25, directed against IgE) has been
registered as add on therapy for the treatment of therapy
resistant, severe allergic asthma. The mechanism of action
is based on reducing serum levels of free circulating IgE and
down-regulating the high-afﬁnity IgE-receptors (FceRI) on
basophils and mast cells.143 When combined with regular
maintenance therapy, Omalizumab effectively improved
disease control allowing reduction of the daily ICS dose in
two-thirds of patients with allergic asthma and/or allergic
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Summing up 100 years of asthma 385rhinitis.144,145 The major drawbacks are its subcutaneous
administration (every 2–4 weeks) and the high costs.
Another promising biological for the treatment of asthma
is Etanercept, a soluble TNF-a receptor. Anti-TNF-a therapy
has been shown to be effective in severe persistent asthma,
possessing a predominant TH-1 cell proﬁle. A recent study
by Berry and colleagues reported marked improvement in
airway hyperresponsiveness, QoL and post-bronchodilator
FEV1 in patients with severe persistent asthma following 10
weeks of treatment with subcutaneous Etanercept com-
pared to placebo.146 Another study in severe asthmatics
showed similar results after 12 weeks of open label
treatment.147 Not unexpectedly, Etanercept failed to
protect against allergen-induced airway inﬂammation and
airway hyperresponsiveness in patients with mild to moder-
ate asthma.148
And although not all targeted therapies can modulate the
asthmatic airway inﬂammation,34,135,149 this speciﬁc ap-
proach has greatly contributed to our understanding of the
immunology of asthma and the therapeutic options. In the
next century, emerging biotechnologies including genomics,
proteonomics, pharmacogenetics and molecular pharmacol-
ogy will mark the future developments for customized or
phenotype-related therapy for asthma and related syn-
dromes.
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